Systemic Therapy for Stubborn Ringworm
For persistent dermatophytosis that has failed topical treatment, initiate oral antifungal therapy with either terbinafine or itraconazole, selecting the agent based on the causative organism: terbinafine for Trichophyton species and itraconazole for Microsporum species or when the organism is unknown. 1
Initial Approach to Treatment Failure
When ringworm persists despite topical therapy, first evaluate for:
- Non-compliance with treatment regimen 1
- Suboptimal drug absorption 1
- Reinfection from contacts or fomites 1
- Emerging terbinafine-resistant strains (particularly T. indotineae) 2
Obtain fungal culture and microscopy before initiating systemic therapy to guide species-directed treatment, especially in chronic or recalcitrant cases. 3
First-Line Systemic Therapy
Terbinafine (Preferred for Trichophyton species)
Terbinafine is fungicidal and highly effective against Trichophyton species (T. rubrum, T. tonsurans, T. violaceum), but has limited efficacy against Microsporum species. 1
Dosing by body weight: 1
- < 20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
- > 40 kg: 250 mg daily for 2-4 weeks
Advantages: Shorter treatment duration improves compliance; potent fungicidal activity with minimal drug interactions. 4
Itraconazole (Preferred for Microsporum or unknown species)
Itraconazole demonstrates activity against both Trichophyton and Microsporum species, making it the preferred choice when the causative organism is unknown or when Microsporum canis is suspected. 1
Dosing: 1
- 50-100 mg daily for 4 weeks, or
- 5 mg/kg/day for 2-4 weeks
- Pulse dosing regimens are effective and may improve compliance 1
Management of Treatment-Refractory Cases
When Initial Therapy Fails
If clinical improvement occurs but mycology remains positive, continue current therapy for an additional 2-4 weeks. 1
If no clinical improvement occurs, switch to second-line therapy: 1
- If terbinafine was used first-line → switch to itraconazole
- If itraconazole was used first-line → switch to terbinafine (for Trichophyton) or griseofulvin (for Microsporum)
Emerging Resistance Concerns
Terbinafine resistance is increasingly reported with Trichophyton indotineae (formerly T. mentagrophytes ITS genotype VIII), which carries mutations in the squalene epoxidase gene (Leu393Phe, Phe397Leu). 5, 2
For confirmed or suspected T. indotineae infections: 2
- Itraconazole 200 mg/day or higher for extended duration is the treatment of choice
- Fluconazole and griseofulvin are generally ineffective 2
- Consider molecular diagnosis and resistance testing in treatment failures 5, 6
Third-Line Options for Refractory Cases
When both terbinafine and itraconazole fail, consider off-label triazoles: 2
- Voriconazole
- Posaconazole
These agents should be reserved for exceptional circumstances when standard therapies have been exhausted. 1, 2
Critical Treatment Principles
Always combine systemic antifungal therapy with topical antifungal agents to maximize efficacy and reduce relapse risk. 5, 3
Minimum treatment duration: 3
- Naïve cases: 2-4 weeks
- Recalcitrant cases: > 4 weeks
The endpoint of treatment is mycological cure, not just clinical improvement—repeat mycology sampling until clearance is documented. 1
Important Caveats
Avoid topical corticosteroids, which are strongly discouraged in tinea management as they can worsen infection and create treatment-refractory disease. 3
Screen and treat household contacts and close contacts, particularly in T. tonsurans infections, as asymptomatic carriers can perpetuate reinfection. 1
For extensive lesions or multisite involvement, systemic plus topical combination therapy is mandatory from the outset rather than topical monotherapy. 3